Phase 2 N=146 BKM120 for Patients With PI3K-activated Tumors
PI3K Pathway Activated Tumors
Primary: Participant Clinical Benefit Response Rate — 15.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Phase 2 N=14 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Phase 2 N=6 A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian Sarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma
Primary: Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or…
Phase 2 N=80 Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Phase 2 N=110 MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Phase 1 N=23 PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
Advanced Breast Carcinoma · Advanced Malignant Solid Neoplasm · Advanced Prostate Carcinoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 2; 0; 0; 0 Participants
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants
Phase 2 N=26 Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) for PI3K GNE-positive Participants Registered to S1400B Treated With GDC-0032. — 1; 13; 5; 1 Participants
Phase 2 N=208 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Phase 2 N=71 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Phase 2 N=106 LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Tumors With CDK4/6 Pathway Activation
Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants
Phase 3 N=579 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast Cancer
Primary: Cohort A: Progression-Free Survival (PFS) — 6.1; 7.4 months — p=0.9237
Phase 2 N=673 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Neoplasms · Solid Tumors · Biliary Cancer
Primary: Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator — 21.0; 19.5; 25.5; 33.3 Percentage of Participants
Phase 2 N=50 A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Phase 2 N=18 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Phase 2 N=37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 2 N=50 NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
HER2-positive Newly Diagnosed, Primary Breast Cancer
Primary: Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants — 32.0; 40.0 Percentage of participants — p=0.811
Phase 2 N=30 Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Recurrent Breast Carcinoma · Stage IIIB Breast Cancer · Stage IIIC Breast Cancer
Primary: Number of Participants With Response Defined Using Response Evaluation Criteria In Solid Tumors (RECIST) — 0; 1; 20; 0 participants
Phase 1 N=146 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Locally Advanced Solid Tumor · Metastatic Solid Tumor · Breast Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 subjects
Phase 2 N=66 A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants
Phase 2 N=22 Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Phase 2 N=21 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Phase 2 N=70 BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Advanced Endometrial Cancer
Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants
Phase 2 N=36 p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=39 Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor · Microsatellite Stable (MSS) Colon Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 0 Participants